Endeavor Venture Fund & Venture Studio

HLTH and ENDEAVOR PARTNERSHIP for Masterclasses! Thrilled to be a new Partner and Anchor in the Health HLTH Community. Endeavor will be delivering a series of Masterclasses on a regular basis over the next year on AI and Healthcare in the areas of drug development & discovery, innovation impacting hospitals including electronic healthcare records, radiology, pathology, surgical suite logistics, discharge planning, improving patient fall risks, and addressing nurse and physician burnout. We will be discussing important partnerships in AI and Healthcare between Emerging Companies, Big Tech, Biopharma, Biotech, Bedtech, Healthtech, and Major Academic Medical Centers. As part of our 20 year development of the Endeavor Healthcare Ecosystem, we've established partnerships with Fortune 500 companies and collaborations with major tech firms, including Microsoft, as well as with Big Pharma, including Sinofi, and leading medical centers such as Mount Sinai, Memorial Sloan Kettering, SUNY Downstate, and Mass General Brigham Hospital. Our focus is on fostering collaboration as we look to integrate AI into the healthcare system. Join us on November 13th for a celebration of collaboration at the Endeavor and Mount Sinai Health Systems Healthcare AI and Technology Investor Summit, from 4:00 PM to 10:00 PM at the offices of Goodwin Proctor in NYC. For more information, please contact us at [email protected]. #Artificialintelligence #VentureCapital #Investing #Entrepreneurship #Startup #Healthcare #HealthTech #MedTech #Funds #DrMartinAlexanderGershon #BetterHealth Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio

NOTEWORTHY AI Growth Strategies for Drug Discovery According to research from the Endeavor analytics team, we are likely in a decade long period of a fluctuating economy and turbulent business growth. Established companies must therefore look to drive and sustain growth by simultaneously building new businesses and transforming their core operations. By creating synergies between core business reinvention and new venture development, companies can achieve greater outcomes than either approach alone would yield. AI in Drug Discovery and Development offers these dual growth mandates for the Biopharma industry, that despite rising investments shows declining pharmaceutical R&D productivity with a staggering 92% drug development failure rate. In recent years, the global economy has faced major disruptions with long-lasting impacts. While inflation has eased in some regions, it remains a significant concern, and geopolitical tensions continue to escalate without resolution. High interest rates and volatile commodity prices persist as well. It’s becoming evident that these challenges may not be short-lived but are likely to shape the future economy. Simultaneously, the market landscape is undergoing fundamental shifts. Corporate longevity is at a historic low, with five of the ten largest companies today having been nonexistent 25 years ago. The average lifespan of a company in the US dropped to less than 20 years. Newer, predominantly digital companies have transformed how industries operate, capturing 8 to 25 percent of market share within 5 years. In light of these trends, corporate reinvention is more critical than ever, especially for established companies seeking sustained growth in the face of rising competition. However, pulling off a successful transformation is challenging. Leaders should consider broadening their focus beyond their core operations to identify new growth opportunities. Indeed, growth can be achieved through a dual transformation strategy, revitalizing the core business while simultaneously building new ventures. This approach not only helps extend the life of established companies but also opens doors to new expansion opportunities, allowing businesses to outpace market growth and create significant value. While executing this strategy can be challenging due to factors like unclear strategic vision, limited funding, or operational complexity, a dual transformation approach can amplify the effects of a successful transformation. According to McKinsey every dollar of revenue from new ventures generates twice the enterprise value of a dollar from core business operations. Moreover, cash flow unlocked from core business transformations can provide the flexibility needed to develop and scale new ventures without pressure from investors. If your company would like to learn more please contact us at [email protected] Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH

🚀 NOTEWORTHY Anti-Aging Innovation Novel Molecule Protects Cells from Cancer and Neurodegenerative Disease The Endeavor research team is excited about a new biology innovation for aging. Researchers at The University of Texas MD Anderson Cancer Center have discovered a small-molecule compound that restores youthful levels of telomerase reverse transcriptase (TERT) —an enzyme essential for telomere maintenance. This breakthrough could pave the way for treating age-related diseases such as Alzheimer's, Parkinson's, heart disease, and cancer. Read more about it here https://shorturl.at/i9lb2 Here’s what stands out: 🧬 Telomere Restoration: TERT helps maintain telomeres (chromosome endings). With age, telomeres shorten—-leading to cell senescence and inflammation. The new compound, TERT-activating compound (TAC), epigenetically reactivates TERT, extending telomeres and reducing DNA damage signals 🧠 Cognitive and Neuromuscular Improvements: In preclinical models, six months of TAC treatment led to new neuron formation in the hippocampus, improved cognitive test performance, enhanced neuromuscular function, and reversed sarcopenia, which is the age-related decline in muscle mass and function. ⏰ Inflammation Reduction: TAC significantly lowered markers inflammaging, a chronic inflammation associated with aging, by repressing the p16 gene, a key factor in cell senescence. This reduction in inflammation suggests that TAC could help mitigate various age-related diseases. The ability to pharmacologically restore youthful TERT levels represents a significant advancement in anti-aging therapies. This approach not only has the potential to extend lifespan but also to improve the quality of life in aging populations. Further clinical studies are needed to confirm these results and explore the full therapeutic potential of TAC. 🌟 What Do You Think? How quickly do you think new therapies and treatments will be developed from this discovery? Let us know in the comments. 👇 Feel free to share your thoughts with comments and likes! 🔄 If you found this insightful, please like, share, and comment to keep the conversation going! Deeper Dive: For a deeper dive and more news like this, subscribe to our newsletter https://lnkd.in/gcFhTvh2 , follow our events on our corporate page https://rb.gy/0c2min , hear prominent thought leaders discussing AI in healthcare on our YouTube https://shorturl.at/vZazG , and follow us on X @endeavorfunds. As a subscriber each week you’ll receive insights about the remarkable innovations in emerging Healthcare Startups, Investments from Venture Capital, and the Go-to-Market Growth Strategies to integrate these technologies into the healthcare system. #Biotechnology #Innovation #VentureCapital #Entrepreneurship #Healthcare #HealthTech #Investment #DrMartinAlexanderGershon #Endeavor Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio

NOTEWORTHY AI Growth Strategies for Drug Discovery According to research from the Endeavor analytics team, we are likely in a decade long period of a fluctuating economy and turbulent business growth. Established companies must therefore look to drive and sustain growth by simultaneously building new businesses and transforming their core operations. By creating synergies between core business reinvention and new venture development, companies can achieve greater outcomes than either approach alone would yield. AI in Drug Discovery and Development offers these dual growth mandates for the Biopharma industry, that despite rising investments shows declining pharmaceutical R&D productivity with a staggering 92% drug development failure rate. In recent years, the global economy has faced major disruptions with long-lasting impacts. While inflation has eased in some regions, it remains a significant concern, and geopolitical tensions continue to escalate without resolution. High interest rates and volatile commodity prices persist as well. It’s becoming evident that these challenges may not be short-lived but are likely to shape the future economy. Simultaneously, the market landscape is undergoing fundamental shifts. Corporate longevity is at a historic low, with five of the ten largest companies today having been nonexistent 25 years ago. The average lifespan of a company in the US dropped to less than 20 years. Newer, predominantly digital companies have transformed how industries operate, capturing 8 to 25 percent of market share within 5 years. In light of these trends, corporate reinvention is more critical than ever, especially for established companies seeking sustained growth in the face of rising competition. However, pulling off a successful transformation is challenging. Leaders should consider broadening their focus beyond their core operations to identify new growth opportunities. Indeed, growth can be achieved through a dual transformation strategy, revitalizing the core business while simultaneously building new ventures. This approach not only helps extend the life of established companies but also opens doors to new expansion opportunities, allowing businesses to outpace market growth and create significant value. While executing this strategy can be challenging due to factors like unclear strategic vision, limited funding, or operational complexity, a dual transformation approach can amplify the effects of a successful transformation. According to McKinsey every dollar of revenue from new ventures generates twice the enterprise value of a dollar from core business operations. Moreover, cash flow unlocked from core business transformations can provide the flexibility needed to develop and scale new ventures without pressure from investors. If your company would like to learn more please contact us at [email protected] Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH

🚀 NOTEWORTHY Anti-Aging Innovation Novel Molecule Protects Cells from Cancer and Neurodegenerative Disease The Endeavor research team is excited about a new biology innovation for aging. Researchers at The University of Texas MD Anderson Cancer Center have discovered a small-molecule compound that restores youthful levels of telomerase reverse transcriptase (TERT) —an enzyme essential for telomere maintenance. This breakthrough could pave the way for treating age-related diseases such as Alzheimer's, Parkinson's, heart disease, and cancer. Read more about it here https://shorturl.at/i9lb2 Here’s what stands out: 🧬 Telomere Restoration: TERT helps maintain telomeres (chromosome endings). With age, telomeres shorten—-leading to cell senescence and inflammation. The new compound, TERT-activating compound (TAC), epigenetically reactivates TERT, extending telomeres and reducing DNA damage signals 🧠 Cognitive and Neuromuscular Improvements: In preclinical models, six months of TAC treatment led to new neuron formation in the hippocampus, improved cognitive test performance, enhanced neuromuscular function, and reversed sarcopenia, which is the age-related decline in muscle mass and function. ⏰ Inflammation Reduction: TAC significantly lowered markers inflammaging, a chronic inflammation associated with aging, by repressing the p16 gene, a key factor in cell senescence. This reduction in inflammation suggests that TAC could help mitigate various age-related diseases. The ability to pharmacologically restore youthful TERT levels represents a significant advancement in anti-aging therapies. This approach not only has the potential to extend lifespan but also to improve the quality of life in aging populations. Further clinical studies are needed to confirm these results and explore the full therapeutic potential of TAC. 🌟 What Do You Think? How quickly do you think new therapies and treatments will be developed from this discovery? Let us know in the comments. 👇 Feel free to share your thoughts with comments and likes! 🔄 If you found this insightful, please like, share, and comment to keep the conversation going! Deeper Dive: For a deeper dive and more news like this, subscribe to our newsletter https://lnkd.in/gcFhTvh2 , follow our events on our corporate page https://rb.gy/0c2min , hear prominent thought leaders discussing AI in healthcare on our YouTube https://shorturl.at/vZazG , and follow us on X @endeavorfunds. As a subscriber each week you’ll receive insights about the remarkable innovations in emerging Healthcare Startups, Investments from Venture Capital, and the Go-to-Market Growth Strategies to integrate these technologies into the healthcare system. #Biotechnology #Innovation #VentureCapital #Entrepreneurship #Healthcare #HealthTech #Investment #DrMartinAlexanderGershon #Endeavor Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio

NOTEWORTHY AI Growth Strategies for Drug Discovery According to research from the Endeavor analytics team, we are likely in a decade long period of a fluctuating economy and turbulent business growth. Established companies must therefore look to drive and sustain growth by simultaneously building new businesses and transforming their core operations. By creating synergies between core business reinvention and new venture development, companies can achieve greater outcomes than either approach alone would yield. AI in Drug Discovery and Development offers these dual growth mandates for the Biopharma industry, that despite rising investments shows declining pharmaceutical R&D productivity with a staggering 92% drug development failure rate. In recent years, the global economy has faced major disruptions with long-lasting impacts. While inflation has eased in some regions, it remains a significant concern, and geopolitical tensions continue to escalate without resolution. High interest rates and volatile commodity prices persist as well. It’s becoming evident that these challenges may not be short-lived but are likely to shape the future economy. Simultaneously, the market landscape is undergoing fundamental shifts. Corporate longevity is at a historic low, with five of the ten largest companies today having been nonexistent 25 years ago. The average lifespan of a company in the US dropped to less than 20 years. Newer, predominantly digital companies have transformed how industries operate, capturing 8 to 25 percent of market share within 5 years. In light of these trends, corporate reinvention is more critical than ever, especially for established companies seeking sustained growth in the face of rising competition. However, pulling off a successful transformation is challenging. Leaders should consider broadening their focus beyond their core operations to identify new growth opportunities. Indeed, growth can be achieved through a dual transformation strategy, revitalizing the core business while simultaneously building new ventures. This approach not only helps extend the life of established companies but also opens doors to new expansion opportunities, allowing businesses to outpace market growth and create significant value. While executing this strategy can be challenging due to factors like unclear strategic vision, limited funding, or operational complexity, a dual transformation approach can amplify the effects of a successful transformation. According to McKinsey every dollar of revenue from new ventures generates twice the enterprise value of a dollar from core business operations. Moreover, cash flow unlocked from core business transformations can provide the flexibility needed to develop and scale new ventures without pressure from investors. If your company would like to learn more please contact us at [email protected] Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH

NOTEWORTHY Advancements in Supercomputing for Drug Discovery The Endeavor research team is excited about noteworthy news in AI-driven drug discovery involving Recursion Pharmaceuticals. Through a recent collaboration with NVIDIA and the unveiling of their BioHive-2 supercomputer, Recursion aims to revolutionize drug discovery and compete with leading AI models. The collaboration highlights the integration of powerful deep learning algorithms, supercomputing capabilities, and robotics to accelerate drug discovery. This partnership represents a significant step forward in merging digital and physical research realms to address complex biological challenges. We believe the shift from empiricism to computer simulation-driven design will be a major trend in the coming decade, and Recursion is poised to lead this space. Stay tuned for more developments! Read more about their advancements here https://shorturl.at/FsZqR Here’s what stands out: 💡Parallels in Innovation: NVIDIA's Jensen Huang highlighted the shift from empirical methods to computer simulation-driven design in chip technology, paralleling current advancements in biology driven by deep learning, supercomputing, and robotics. He emphasized the importance of bold risk-taking to discover new knowledge beyond just relying on principles and simulations. 🖥️BioHive-2 Supercomputer: Recursion's BioHive-2, the fastest supercomputer owned by a pharmaceutical company, exemplifies their commitment to using AI and computational power to revolutionize drug discovery. This significant investment marks a paradigm shift in the pharmaceutical industry’s approach to tackling biological complexities. ⚖️Balancing Risk and Purpose: Both NVIDIA and Recursion underscored the importance of balancing bold risk-taking with a deeper sense of purpose. They highlighted the urgency and human impact of their work, emphasizing the need to develop treatments for patients swiftly. What do You Think? What are your thoughts on utilizing supercomputing for drug discovery? How might this impact a firm’s approach to developing new therapies? 🔊 👇 Feel free to share your thoughts with comments and likes! 🔄 If you found this insightful, please like, share, and comment to keep the conversation going! Deeper Dive: For a deeper dive and more news like this, subscribe to our newsletter https://lnkd.in/gcFhTvh2 and follow our events on our corporate page https://rb.gy/0c2min and hear prominent thought leaders discussing AI in healthcare on our YouTube https://shorturl.at/vZazG As a subscriber each week you’ll receive insights about the remarkable innovations in emerging Healthcare Startups, Investments from Venture Capital, and the Go-to-Market Growth Strategies to integrate these technologies into the healthcare system. #ArtificialIntelligence #VentureCapital #DigitalHealth #Entrepreneurship #Healthcare #NVIDIA #HealthTech Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio

🚀 Noteworthy News in AI Drug Discovery Xaira's $1B AI Breakthrough: A Game Changer in Drug Discovery The Endeavor research team is excited about a development in AI-powered drug discovery. Xaira Therapeutics has launched with a remarkable $1 billion in funding. Based in San Francisco, this startup is set to revolutionize the pharmaceutical industry by harnessing the power of machine learning and data generation. Xaira’s mission is to accelerate biological targets, protein designs, and antibody therapies, revolutionizing the speed to market of the traditional drug development and discovery process. With a team led by former Genentech CSO Marc Tessier-Lavigne, Xaira is poised to significantly impact how we develop treatments for complex diseases.🔬 “Xaira is in a strong position to both advance fundamental AI research and translate these advances into transformative new medicines and I am excited to have the opportunity to lead the team.” said Tessier-Lavigne. Here’s what stands out: 💰 $1 Billion Funding: Xaira Therapeutics has secured a groundbreaking $1 billion to drive its innovative approach to AI-powered drug discovery. 🖥️ Revolutionary Technology: The startup aims to transform the pharmaceutical industry with advanced machine learning to identify biological targets and develop new therapies. 👨🔬 Experienced Leadership: Led by former Genentech CSO Marc Tessier-Lavigne and supported by top venture capital firms, Xaira is poised to make significant strides in developing treatments for complex diseases. By leveraging these technologies, Xaira is set to accelerate the development of new therapies. This innovative platform holds the promise of more precise identification of biological targets and faster breakthroughs in treatment, ultimately leading to more effective solutions for complex diseases.🔍 How do you think integrating AI into drug discovery will impact the future of medicine and patient care? What potential does AI have in accelerating drug discovery and reducing development costs? 👇 Feel free to share your thoughts with comments and likes! 🔄 If you found this insightful, please like, share, and comment to keep the conversation going! For a deeper dive and more news, subscribe to our newsletter https://lnkd.in/gcFhTvh2 and follow our events on our corporate page https://rb.gy/0c2min and our YouTube https://lnkd.in/gnAExDPR As a subscriber each week you’ll receive insights about the remarkable innovations in emerging Healthcare Startups, Investments from Venture Capital, and the Go-to-Market Growth Strategies to integrate these technologies into the healthcare system. Read more here. https://shorturl.at/2dRLn #artificialintelligence #venturecapital #investing #digitalhealth #entrepreneurship #healthcare #fundraising #healthtech #drugdiscovery #betterhealth #endeavorventurefunds #martinalexandergershon Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio

Thrilled to be working with the HSBC Innovation team!  The Synergy of Innovation and Strategy At Endeavor, we believe that the convergence of scientific discoveries, advanced medicine, and cutting-edge technology is on the verge of delivering monumental breakthroughs. Our strategic approach involves not only investing in groundbreaking technologies but also fostering collaborations with major corporations across Big Tech, HealthTech, Big Pharma, MedTech, Biotech and Finance. This synergy is crucial for successful commercialization and scaling of disruptive innovations and we are appreciative of the collaboration with HSBC. Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio https://lnkd.in/eT6tyyJZ